[go: up one dir, main page]

WO2003002061A3 - Compositions and methods for treating atherosclerosis - Google Patents

Compositions and methods for treating atherosclerosis Download PDF

Info

Publication number
WO2003002061A3
WO2003002061A3 PCT/US2002/020350 US0220350W WO03002061A3 WO 2003002061 A3 WO2003002061 A3 WO 2003002061A3 US 0220350 W US0220350 W US 0220350W WO 03002061 A3 WO03002061 A3 WO 03002061A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
pro
nucleic acid
provides
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/020350
Other languages
French (fr)
Other versions
WO2003002061B1 (en
WO2003002061A2 (en
Inventor
Roger A Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
San Diego State University Research Foundation
San Diego State University
Original Assignee
San Diego State University Research Foundation
San Diego State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by San Diego State University Research Foundation, San Diego State University filed Critical San Diego State University Research Foundation
Priority to AU2002345932A priority Critical patent/AU2002345932A1/en
Publication of WO2003002061A2 publication Critical patent/WO2003002061A2/en
Publication of WO2003002061A3 publication Critical patent/WO2003002061A3/en
Publication of WO2003002061B1 publication Critical patent/WO2003002061B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a nucleic acid having a nucleotide sequence encoding an inhibitor of a proatherogenic molecule operationally linked to a macrophage-specific expression element. The invention also provides a recombinant macrophage expressing a nucleic acid encoding an inhibitor of a pro-atherogenic molecule. The invention further provides a method for inhibiting or reducing atherosclerosis including administering to an individual a population of recombinant cells expressing a nucleic acid encoding an inhibitor of a pro-atherogenic molecule. Additionally, the invention provides a method for inhibiting or reducing atherosclerosis including administering to an individual a nucleic acid encoding an inhibitor of a pro-atherogenic molecule, the inhibitor of a pro-atherogenic molecule operationally linked to a macrophage-specific expression element.
PCT/US2002/020350 2001-06-26 2002-06-26 Compositions and methods for treating atherosclerosis Ceased WO2003002061A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002345932A AU2002345932A1 (en) 2001-06-26 2002-06-26 Compositions and methods for treating atherosclerosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89336601A 2001-06-26 2001-06-26
US09/893,366 2001-06-26

Publications (3)

Publication Number Publication Date
WO2003002061A2 WO2003002061A2 (en) 2003-01-09
WO2003002061A3 true WO2003002061A3 (en) 2003-11-06
WO2003002061B1 WO2003002061B1 (en) 2003-12-24

Family

ID=25401440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/020350 Ceased WO2003002061A2 (en) 2001-06-26 2002-06-26 Compositions and methods for treating atherosclerosis

Country Status (2)

Country Link
AU (1) AU2002345932A1 (en)
WO (1) WO2003002061A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101843905B (en) * 2009-03-27 2015-04-08 中国医学科学院基础医学研究所 Application of PON gene cluster in preparing medicaments for treating atherosclerosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047734A1 (en) * 1999-02-12 2000-08-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047734A1 (en) * 1999-02-12 2000-08-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BENOIT P. ET AL.: "Somatic gene transfer of human ApoA-I inhibits athersclerosis progression in mouse models", CIRCULATION, vol. 99, January 1999 (1999-01-01), pages 105 - 110, XP002965380 *
KAWASHIRI M. ET AL.: "Gene therapy for lipid disorders", CURR. CONTROL TRIALS CARDIOVASC. MED., vol. 1, October 2000 (2000-10-01), pages 120 - 127, XP002965382 *
RONG J.X. ET AL.: "High-density lipoprotein: gene based approaches to the prevention of atherosclerosis", ANNALS OF MEDICINE, vol. 32, December 2000 (2000-12-01), pages 642 - 651, XP002965383 *
RUBIN E.M. ET AL.: "Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearances of two new high density lipoprotein size subclasses", PROC. NATL. ACAD. SCI. USA, vol. 88, January 1991 (1991-01-01), pages 434 - 438, XP002965381 *

Also Published As

Publication number Publication date
WO2003002061B1 (en) 2003-12-24
WO2003002061A2 (en) 2003-01-09
AU2002345932A1 (en) 2003-03-03

Similar Documents

Publication Publication Date Title
WO2001064898A3 (en) Genes encoding denitrification enzymes
WO2002042424A3 (en) Seed-preferred regulatory elements and uses thereof
MXPA03002218A (en) Antimicrobial peptides and methods of use.
WO2003093441A3 (en) A method of regulating gene expression
FR2822164B1 (en) POLYPEPTIDES DERIVED FROM POLYMERASE RNAS, AND USES THEREOF
EP1390394A4 (en) Compositions and methods for recombinational cloning of nucleic acid molecules
DE60229050D1 (en) PROCESS FOR THE PREPARATION OF ASCORBIC ACID INTERMEDIATE PRODUCTS IN HOST CELLS
ATE275956T1 (en) ALTERATION OF DNA METHYLTRANSFERASE THROUGH COMBINATION THERAPY
WO2003048319A3 (en) Nucleotide sequences encoding proteins conferring abiotic stress tolerance in plants
WO2002060917A3 (en) Method to treat hemophilia
WO2003097834A3 (en) A method for in vitro molecular evolution of protein function
EP1341909B8 (en) A method for in vitro molecular evolution of protein function
FI961202A0 (en) The Grb3-3 gene, its variants and their uses
WO2003057843A8 (en) Methods and materials for modulating trpc4
DE60043470D1 (en) Herbal Defensins
DE50213015D1 (en) LIPASE VARIANTS
WO2003002061A3 (en) Compositions and methods for treating atherosclerosis
PL1711612T3 (en) Expression cassettes for the bi-directional transgenic expression of nucleic acids in plants
WO2003057847A3 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
DE60230071D1 (en) METHOD FOR THE PRODUCTION OF PROTAMINE
DK1633873T3 (en) Bacteria with increased levels of protein secretion, nucleotide sequences encoding a SecA protein with increased levels of protein secretion, and method for producing proteins
WO2003040342A3 (en) Method for generation of modular polynucleotides using solid supports
WO2001053470A3 (en) Nucleic acid and amino acid sequences encoding a de novo dna methyltransferase
WO2003076668A3 (en) Method for identifying specific rna-inhibitors
WO2002103022A3 (en) Transgenic cells expressing clucosyltransferases which glucosylate parabenzoic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
B Later publication of amended claims

Free format text: 20030619

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP